JPRN-jRCT2080224117已完成1 期
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Provide written informed consent.
- •2. Is >= 20 years.
- •3. Has histologically or cytologically confirmed, locally advanced, metastatic cancer.
- •4. Patient has measurable disease.
- •5. ECOG performance status 0 or 1.
- •6. Able to take medications orally.
- •7. Adequate organ function.
- •8. Have a negative pregnancy test.
- •9. Willing and able to comply with scheduled visits and study procedures.
排除标准
- •1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
- •2. History and/or current evidence of clinically significant ectopic mineralization/calcification.
- •3. History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination.
- •4. A serious illness or medical condition(s)
研究者
相似试验
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-004810-16-DETaiho Oncology Inc385
已完成
2 期
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONSNL-OMON48846Taiho Oncology, Inc.20
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-004810-16-PTTaiho Oncology Inc385
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesEUCTR2013-004810-16-NLTaiho Oncology Inc835
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesEUCTR2013-004810-16-GBTaiho Oncology Inc385